Superpotent children's acetaminophen recalled; Catalent expands highly potent packaging; BMS and Lonza extend agreement;

> Aidarex Pharmaceuticals is recalling 531, 20-count bottles of its 500-mg ciprofloxacin antibiotic tablets manufactured by India's Unique Pharmaceutical Laboratories after a tablet of pain drug tramadol was found in one. Notice

> Bio-Pharm is recalling 35,739 bottles of Rugby Children's Pain and Fever Acetaminophen Oral Suspension because it may be superpotent. Notice

> Catalent Pharma Solutions ($CTLT) has started work on an expansion of its highly potent and cytotoxic clinical drug packaging capabilities at its campus in Kansas City, MO. Release

> Bristol-Myers Squibb ($BMY) and Lonza have expanded a biologics manufacturing agreement for Lonza to produce commercial quantities of a second BMS biologic at its mammalian manufacturing facility in Portsmouth, NH. Report

And Finally... An FDA warning letter indicates that drug compounder Pharmagen closed its facility in Stamford, CT, after an agency inspection found problems with the sterile drug work there. Letter

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.